DAYLIGHT
(2025)Objective
To evaluate whether extended non-gated CT angiography (CTA) during acute stroke imaging improves detection of cardioaortic thrombi compared to standard CTA.
Study Summary
Intervention
Head-to-neck CTA extended ≥6 cm below the carina during acute stroke code vs. standard head and neck CTA.
Inclusion Criteria
Adults ≥18 years with suspected ischemic stroke or TIA assessed during acute code stroke activation; excluded if contraindicated for contrast.
Study Design
Arms: Extended CTA vs. Standard CTA
Patients per Arm: Extended CTA: 226; Standard CTA: 239
Outcome
Bottom Line
Extended CT angiography significantly improves detection of cardioaortic thrombus without delaying stroke care or increasing adverse effects, suggesting a simple and feasible strategy to enhance early cardiac source detection.
Major Points
- Randomized, blinded-endpoint trial comparing standard vs extended CT angiography in acute stroke/TIA
- Detection of cardioaortic thrombus significantly higher in extended CT group (8.8% vs. 1.7%; OR 5.70, 95% CI 1.92–16.96, p=0.002)
- No delay in imaging or acute treatments (median time 21 min vs 20 min, p=0.67)
- Number needed to screen = 14 for detection of 1 thrombus
- Additional radiation exposure was minimal (1.2 mSv more)
- Extended CTA may allow early thrombus detection before it is dissolved by thrombolysis or anticoagulation
Study Design
- Study Type
- Randomized, open-label, blinded-endpoint trial
- Randomization
- Yes
- Blinding
- Blinded outcome adjudication
- Sample Size
- 830
- Follow-up
- ≥30 days
- Centers
- 1
- Countries
- Canada
Primary Outcome
Definition: Detection of confirmed or highly suspected cardioaortic thrombus ≥30 days after qualifying event
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| 1.7% | 8.8% | - (1.92–16.96) | 0.002 |
Limitations & Criticisms
- Single-centre design may limit external validity
- Incomplete follow-up with advanced cardiac imaging
- Possible underdetection or misclassification of thrombi
- No evaluation of long-term clinical outcomes such as recurrence or mortality
Citation
Lancet Neurol. 2025;24:489–499